Xcout Intel
Atrium Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Atrium Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Atrium Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Atrium Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Atrium Therapeutics, Inc. at a glance
Atrium Therapeutics, Inc. is a biotechnology company headquartered in San Diego, United States. It is publicly listed (RNA) with a market capitalisation of $143.7M. Xcout tracks 16 named people at Atrium Therapeutics, Inc., including Kathleen Gallagher (President, CEO & Director). Xcout recorded 7 job postings from Atrium Therapeutics, Inc. in the last 90 days.
Atrium Therapeutics, Inc. leadership
- Kathleen GallagherPresident, CEO & Director
- Brendan WinslowChief Financial Officer
- Husam S. Younis, PhD, PharmDChief Scientific Officer
- Husam YounisChief Scientific Officer
- Rocio Martin HoyosChief Strategy Officer
- Stephanie KenneyChief Corporate Affairs Officer
10 more named people on record for Atrium Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Atrium Therapeutics, Inc.
Xcout recorded 7 job postings from Atrium Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Atrium Therapeutics, Inc.'s hiring signals →
Top 12 Atrium Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Atrium Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Similar biotechnology company
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
Similar biotechnology company
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Similar biotechnology company
Edgewise Therapeutics is a biopharmaceutical company that develops novel therapeutics for individuals facing serious cardiovascular diseases, such as hypertrophic cardiomyopathy and heart failure. The company focuses on muscle science and precision therapies to address unmet medical needs in patients and families.
Similar biotechnology company
Autobahn Therapeutics, Inc. is a privately held biopharmaceutical company with its corporate office and headquarters located in San Diego, California, focused on restoring hope for patients.
Similar biotechnology company
cAMPfield Therapeutics is a biotechnology research company headquartered in San Diego, California. The company focuses on discovering and developing innovative therapeutic treatments targeting specific biological pathways.
Similar biotechnology company
XyloCor Therapeutics is a clinical-stage biopharmaceutical company headquartered in King of Prussia, Pennsylvania, focused on developing novel gene therapies for advanced coronary artery disease. The company is dedicated to improving patient outcomes through innovative cardiovascular treatments.
Life Sciences (Therapeutics)
DTx Pharma, Inc. is a privately held biotechnology company based in San Diego, California, that addresses the challenges associated with delivering RNA-based therapeutics.
Similar biotechnology company
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Similar biotechnology company
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Similar biotechnology company
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company located in San Diego, California. The company is committed to developing cutting-edge RNA-targeted therapeutics to treat various genetic and severe diseases. ADARx focuses on translating scientific research into life-saving medicines through its proprietary drug discovery pipeline.
Similar biotechnology company
Cardior Pharmaceuticals GmbH is a clinical-stage biopharmaceutical company headquartered in Hannover, Germany. Established in 2016, the company focuses on discovering and developing RNA-based therapeutics for the prevention and treatment of heart diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Atrium Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Atrium Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →